CEO of TechBio Platform Company Recruited by Occam Global
In October 2024, Occam recruited Thomas McCauley, PhD, as President and CEO of Neptune Bio, a NYC-based TechBio platform company backed by Lux Capital and KdT Ventures.
Tom joins Neptune from Omega Therapeutics, a Flagship incubated epigenetics platform company, where he has served as Chief Scientific Officer (CSO) from the company's infancy through crossover and a public offering.
Previously, Tom served as CSO of Macrolide Pharma and Translate Bio (acquired by Sanofi for $3.2B). He began his industrial career at Shire.
Tom received a BS and MEng in Applied and Engineering Physics from Cornell and his PhD in Condensed Matter and Materials Physics from the University of Alabama.
About Neptune Bio
Neptune Bio is dedicated to discovering combinatorial cures by identifying the distinct conditions that trigger cellular changes. Their platform integrates groundbreaking biological data with advanced artificial intelligence (AI) to model complex gene synergies, paving the way for the development of new combinatorial therapies.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.